Ask1 inhibitor and preparation method and use thereof

A compound as shown in formula (II):

• wherein
• is selected from a single bond or a double bond;
• X is selected from the group consisting of C(R3), CH(R3), N and N(R3);
• Y is selected from the group consisting of N(R5) and O;
• ring A is selected from the group consisting of phenyl and 5- to 6-membered heteroaryl;
• R1 is selected from 5- to 10-membered heteroaryl optionally substituted with one, two or three R group(s);
• R2 is selected from the group consisting of H, F, Cl, Br, I, OH, and NH2, or selected from the group consisting of C1-6 alkyl, C1-3 heteroalkyl, 5- to 6-membered heterocycloalkyl, phenyl and 5- to 6-membered heteroaryl, each optionally substituted with one, two or three R group(s);
• R3 is selected from the group consisting of H, F, Cl, Br, I, OH, and NH2;
• R4 is selected from H, or selected from the group consisting of C1-3 alkyl and C1-3 alkoxy;
• R5 is selected from H, or selected from the group consisting of C1-8 alkyl, C3-7 cycloalkyl and 3- to 6-membered heterocycloalkyl, each optionally substituted with one, two or three R group(s);
• R6 is selected from H, or selected from C1-6 alkyl;
• or R5 and R6 are joined together to form a 5- to 6-membered ring;
• R is selected from the group consisting of H, F, Cl, Br, I, OH, and NH2, and NH2—(C═O)—, or selected from the group consisting of C1-3 alkyl, C1-3 alkoxy, C1-3 alkyl-NH—(C═O)—, C1-3alkyl-S(═O)2—, C3-6cycloalkyl, 3- to 6-membered heterocycloalkyl and phenyl;
• the “hetero” in the 5- to 10-membered heteroaryl, C1-3 heteroalkyl, 5- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, and 3- to 6-membered heterocycloalkyl is respectively and independently selected from the group consisting of —NH—, N, —O—, —S—, —S(═O)2— and —NH—C(═O)—;
• in any of the above cases, the number of heteroatoms or heteroatomic groups is respectively and independently selected from 1, 2 or 3,
• a pharmaceutically acceptable salt and a tautomer thereof.